Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ENEMENEMYNEMOon Nov 16, 2019 8:32pm

153 Views

Post# 30361038

RE:Quick questions for the pros

I'm not sure where the comment of a "difference" in relative risk comes from. RR is the chance that one event happens over another. I'm not familiar with comparing RR from different components of a study.
Now 18% sounds good but a skilled promoter can twist the sh*t out of statistics to make anything sound good

IE: Drug X shows a 50% reduction in death. (Sounds Great!!!)...
Here's the stats...Death From Drug X 1%....Death from from Drug Y 2%

Not much difference...1% vs 2%.... but it's 50%...or 100% if you'd really sleazy...

Bullboard Posts

Unique Battery Metals opportunity in Quebec